

Insecticides that function like nicotine

Application of a NAM battery to assess potential adverse effects

J. Blum, D. Loser, Y. Johansson, M. Hinojosa, R. von Hellfeld, T. Braunbeck, M. Zana, A. Dinnyes, K. Grillberger, G. Ecker, B. M.A. van Vugt-Lussenburg, B. van der Burg, I. Gardner, U. Kraushaar, M. Leist, A. Forsby, S.H. Bennekou

Coordinated by: DTU, UKN, SU

Regulatory context: Pesticides

New approach methods used in case study


- Testing in a broad battery of new approach methods (NAM)
- Assessment of 6 neonicotinoids and 2 metabolites
- Nicotine as well-known neurodevelopmental toxicant is reference substance for testing
- Transcriptional profiling of test systems used for testing

Key neurodevelopmental processes and cell survival						
Test Method	UKN2	UKN4	UKN5	RoFA	TD42 iPSCs	SHSY5Y cells
Test System	neural crest cells	LUHMES (CNS neurons)	hiPSC neurons (PNS neurons)	hiPSC differentiation into neuronal		
Endpoint 1	cytotoxicity	cytotoxicity	cytotoxicity	cytotoxicity	cytotoxicity	cytotoxicity
Endpoint 2	migration	neurite outgrowth	neurite outgrowth	rosette formation	-	-

Biochemical/Signalling		Zebrafish	In silico
Test Method	CALUX assays	FET (OECD 236)	Docking
Test System	reporter gene assays in U2OS	Fish embryos	IFD; Schrödinger Release 2020-2
Endpoint 1	cytotoxicity	Lethality	representative docking poses
Endpoint 2	receptor- or stress pathway	developmental alterations	Internal exposure


Neuronal signaling alterations via nicotine & neonicotinoids

- Key neurodevelopmental processes tested in NAM battery are not affected
- Receptor docking modeling confirmed interaction at human receptors
- Receptor signaling measurements indicated: **nicotine very potent activating and desensitizing; 4 (of 6) neonicotinoids are active and desensitizing**
- Identification of a metabolite with similar potency as nicotine (desnitro-imidacloprid)



Potential neurodevelopmental effects of tested pesticides

- Concern for developmental neurotoxicity based on molecular actions similar to those of nicotine
- We built a putative adverse outcome pathway (AOP) based on nicotine
- Case study provided:
 - Mechanistic understanding of molecular initiating event (MIE) & early key events (KE)
 - High evidence for early KEs - signaling data in two cell systems (LUHMES & SH-SY5Y)



CS publications: Loser et al., <https://doi.org/10.1007/s00204-021-03031-1> & Loser et al., <https://doi.org/10.1007/s00204-021-03168-z>

